Tumorigenicity and immunogenicity of cytokine-AML cells. (A) SJL/J mice (8 to 10 mice for each type of experiment) were injected IV with 105 or 106 live GM-AML, IL-4–AML, or TNF-α–AML cells (cytokine-AML). Control mice were injected with 105 or 106 mock-infected AML cells. All mice injected with 105 cytokine-AML (•) and 106GM-AML cells (▪) rejected their leukemia. Mice injected with 105 (▨) or 106 (□) control cells developed leukemia at the expected interval. Mice injected with 106IL-4–AML (▴) had 1 week and those injected with 106TNF-α–AML cells (○) had 2 weeks of prolonged survival. (B) SJL/J mice (8 to 10 mice for each type of experiment) were vaccinated IV (solid arrow) with 105 irradiated (3,200 cGy) GM-AML (▪), IL-4–AML (▴), or TNF-α–AML cells (○) or mock-infected control cells (▨) and were challenged 2 weeks later (open arrow) with 105 live wild-type AML cells. GM-AML–vaccinated mice survived tumor challenge, whereas challenge was lethal to all other groups of mice.
